Sample Report
Sample Pain & Anesthesia Report
See how your genetic variants affect pain medications and anesthesia response. Your report follows the same structure — personalized to your genetics.
What's Inside Your Report
Every Pain & Anesthesia Report includes these sections, covering 5 genes across pain sensitivity, opioid response, and medication metabolism.
Summary Snapshot
A quick overview of how many actionable scenarios were identified, genes analyzed, and what to do next.
What We See in Your Data
A plain-language synthesis connecting your genetic variants to real-world pain and anesthesia implications.
Scenario Cards
Each scenario explains a specific clinical situation — what it means, which genes are involved, and what to discuss with your provider.
Medications Table
Pain and anesthesia medications mapped to your genetic results with action flags and clinical reasoning.
Limitations & Disclaimers
Transparent disclosure of what this report can and cannot tell you, including gene coverage and evidence level.
Pain & Anesthesia Report — Full Sample
Sample Data — Not Your Results
Pain & Anesthesia Report
April 2026
Based on pharmacogenomic research for pain management and anesthesia
Summary Snapshot
Multiple Actionable FindingsYour genetics suggest several important considerations for pain management and anesthesia. Multiple variants affect how you process pain signals and metabolize common pain medications.
Do this next: Share this report with your pain specialist or anesthesiologist before any procedure or new pain medication.
What We See in Your Data
Your CYP2D6 result (*1/*4) means you carry one non-functional allele, placing you in the poor metabolizer category. Codeine and tramadol rely on CYP2D6 to convert into their active forms — for you, these medications are unlikely to provide adequate pain relief at standard doses. Your OPRM1 variant (A/G at rs1799971) is associated with reduced opioid receptor binding, which may mean standard opioid doses provide less analgesic effect. Combined with your COMT result (Met/Met at rs4680), which is linked to lower pain thresholds and higher pain sensitivity, your overall pain management profile suggests a need for careful medication selection and dose adjustment. Your BDNF variant (Val/Met) and ANKK1 variant further contribute to how you experience and recover from pain.
Your Scenarios
Codeine and tramadol require CYP2D6 activation — your enzyme activity is too low for adequate conversion.
Genes Involved
CYP2D6 *1/*4 — Poor Metabolizer
CYP2D6 converts codeine to morphine and tramadol to its active metabolite O-desmethyltramadol. As a poor metabolizer, you produce significantly less of these active compounds. Clinical studies show poor metabolizers achieve less than 10% of the analgesic effect compared to normal metabolizers. This is not a matter of dose adjustment — these medications are fundamentally ineffective for your genotype.
Recommendations
- Codeine and tramadol should generally be avoided — they will not convert to their active forms effectively.
- Alternative analgesics that do not depend on CYP2D6 (such as morphine, oxymorphone, or non-opioid options) may be more appropriate.
- Discuss this finding with your prescriber before any procedure where codeine or tramadol might be prescribed.
- If you have previously found codeine ineffective, this result explains why.
References: CPIC Codeine Guideline 2020, PMID:24458010, PMID:31562822
Your opioid receptor variant is associated with reduced binding affinity and lower analgesic response.
Full scenario with genes involved, explanation, and recommendations in your report
Your COMT variant is associated with lower enzyme activity and heightened pain sensitivity.
Full scenario with genes involved, explanation, and recommendations in your report
A BDNF variant contributes to differences in how pain signals are transmitted and modulated.
Full scenario with genes involved, explanation, and recommendations in your report
An ANKK1/DRD2 variant affects dopamine receptor density, influencing pain recovery and reward processing.
Full scenario with genes involved, explanation, and recommendations in your report
4 additional scenarios with full explanations, gene details, and recommendations in your personalized report
Pain & Anesthesia Medications
| Medication | Category | Status | Reason |
|---|---|---|---|
| codeine (Tylenol #3) | Opioid Analgesic | Action Required | CYP2D6 Poor Metabolizer — will not convert to active morphine effectively |
| tramadol (Ultram) | Opioid Analgesic | Action Required | CYP2D6 Poor Metabolizer — inadequate conversion to O-desmethyltramadol |
| hydrocodone (Vicodin) | Opioid Analgesic | Action Required | CYP2D6 Poor Metabolizer — reduced conversion to hydromorphone |
| morphine (MS Contin) | Opioid Analgesic | OPRM1 A/G — may require higher doses for adequate analgesia |
| oxycodone (OxyContin) | Opioid Analgesic | OPRM1 A/G — altered receptor binding may reduce efficacy |
+11 more medications checked in your full report
Limitations & Disclaimers
- This report evaluates CYP2D6, OPRM1, COMT, BDNF, and ANKK1 only. Other genes influencing pain response (e.g., SCN9A, ABCB1, CYP3A4) are not included.
- Genotyping from consumer DNA kits may not capture all star alleles or structural variants. Clinical-grade testing may identify additional variants.
- Pain is multifactorial — genetics is one component alongside psychological, environmental, and contextual factors.
- OPRM1, COMT, BDNF, and ANKK1 findings are based on research-level evidence and are not yet included in CPIC clinical guidelines.
- Medication decisions should always be made with a qualified healthcare provider who can consider your complete clinical picture.
- This report does not account for drug-drug interactions, organ function, or other clinical variables that affect medication response.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
Get your personalized pain & anesthesia report
Upload your 23andMe or AncestryDNA raw data. Your Pain & Anesthesia Report is $39 — one-time, no subscription.
Get Your Pain & Anesthesia Report — $39Free Upload vs. Pain & Anesthesia Report
Everyone gets free trait insights after uploading. The Pain & Anesthesia Report maps your variants to specific pain medications and anesthesia considerations.
Free with upload
- 9 trait insights (caffeine, lactose, etc.)
- Basic metabolizer status for key enzymes
- Which pain medications are affected
- Pain sensitivity and opioid response scenarios
- Anesthesia-specific recommendations
- Medication-by-medication action table
Pain & Anesthesia Report
$39- Everything in free, plus:
- 5 genes analyzed across pain and anesthesia pathways
- Scenario-based findings with clinical context
- 14 pain medications mapped to your genetic results
- Opioid response and sensitivity profile
- Anesthesia pre-procedure discussion guide
Pain Pharmacogenomics from DNA You Already Have
Clinical pain PGx testing costs $300+ and requires a new sample, a prescription, and often insurance pre-authorization. The Pain & Anesthesia Report is $39 using raw data from 23andMe or AncestryDNA — data you already have.
Both approaches reference the same pharmacogenomic research for opioid metabolism and pain sensitivity. The difference: you already have the data.
Built on Pharmacogenomic Evidence
CYP2D6 findings reference CPIC clinical guidelines for codeine and tramadol. OPRM1, COMT, BDNF, and ANKK1 findings are based on peer-reviewed pharmacogenomic research with consistent replication across multiple studies.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Ready to See Your Pain & Anesthesia Results?
Upload your 23andMe or AncestryDNA raw data. Your personalized Pain & Anesthesia Report is $39 — one-time, no subscription.